A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

NCT04474470 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Squamous Cell Carcinoma of Head and Neck
Colorectal Adenocarcinoma
Metastatic Solid Tumor
Recurrent Solid Tumor
Head and Neck Cancer

Interventions

DRUG: NT219
DRUG: NT219 and ERBITUX® - Dose Escalation
DRUG: NT219 and ERBITUX® - Expansion

Sponsor

TyrNovo Ltd.